Skip to content
Bored Studies
RecruitingPhase 3

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Bristol-Myers Squibb · NCT06979453

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 12–17 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
366
US sites recruiting
27
Study start
December 3, 2025
Record last updated
September 3, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

Being studied: Deucravacitinib; Placebo

Conditions: Plaque Psoriasis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Participants must have stable plaque psoriasis for 6 months or more prior to Screening.
  • Participants must have moderate to severe psoriasis defined by:.

i) Psoriasis Area and Severity Index (PASI) ≥ 12, at screening visit and Day 1.

ii) Static Physician's Global Assessment (sPGA) ≥ 3, at screening visit and Day 1.

iii) Body Surface Area (BSA) ≥ 10% involvement, at screening visit and Day 1.

  • A female (as assigned at birth) participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:.

i) Is not an individual of childbearing potential (IOCBP).

ii) Is an IOCBP and using a contraceptive method that is highly effective (with a failure rate of \< 1% per year) during the study intervention period and for at least 3 days after discontinuation of the study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.

Exclusion Criteria

  • Participants must not weigh \< 30.0 kg at Screening and Day 1.
  • Participants must not have non-plaque psoriasis (ie, guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis) or any skin condition other than plaque psoriasis that could interfere with assessments of treatment effect at Screening or Day 1.
  • Participants must not have a history of serious bacterial, fungal, or viral infection requiring hospitalization and intravenous (IV) antimicrobial treatment within 60 days prior to Day 1.
  • Participants must not have any untreated bacterial infection within 60 days prior to Day 1.
  • Participants must not have any ongoing evidence of chronic bacterial infection (eg, chronic pyelonephritis, chronic osteomyelitis, chronic bronchiectasis).
  • Participants must not have herpes simplex/zoster, active tuberculosis (TB), hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV) infection-related exclusions.
  • Participants must not have received live vaccines or BCG within 60 days prior to Day 1 or plans to receive a live vaccine during the study, or within 60 days after completing study intervention.
  • Participants must not have had any prior exposure to deucravacitinib.
  • Participants must not have received any medication that is specifically prohibited.
  • Participants must not have a laboratory finding that is exclusionary.
  • Participants must not have any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, psychiatric, neurologic, immunologic, or local active infection/infectious illness) that, in the investigator's judgment or after consultation with the Sponsor's Medical Monitor, will substantially increase the risk to the participant if he or she participates in the study.
  • Participants must not have cancer or history of cancer (solid organ or hematologic including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Recruiting US locations

  • Center For Dermatology Clinical Research, Inc.

    Fremont, CA 94538

    Site contact: Sunil Dhawan, Site 0090 · 510-599-4750

  • Dermatology Research Associates

    Los Angeles, CA 90045

    Site contact: Howard Sofen, Site 0006 · 310-337-7171

  • Northridge Clinical Trials

    Northridge, CA 91325

    Site contact: Navid Ezra, Site 0214 · 818-350-7483

  • Golden State Dermatology - Walnut Creek - Ygnacio Valley Road

    Walnut Creek, CA 94598

    Site contact: Michael Wang, Site 0243 · 507-261-3758

  • Paradigm Clinical Research, LLC

    Wheat Ridge, CO 80033

    Site contact: Kimberly Neyman, Site 0231 · 303-463-1947

  • Life Clinical Trials

    Margate, FL 33063

    Site contact: Eli Saleeby, Site 0185 · 954-849-0902

  • Skin Research of South Florida

    Miami, FL 33173

    Site contact: Giovanna Ciocca, Site 0043 · 305-707-9852

  • Wellness Clinical Research

    Miami Lakes, FL 33016

    Site contact: David Rodriguez, Site 0014 · 786-483-7856

  • MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research

    Tampa, FL 33607

    Site contact: Stephen Lockwood, Site 0070 · 813-948-7550

  • USF Health

    Tampa, FL 33612

    Site contact: Sharon Albers, Site 0171 · 813-974-4381

  • Dermatology Affiliates Research Institute

    Atlanta, GA 30305

    Site contact: Adebayo Akinsola, Site 0244 · 770-733-1077

  • Advanced Medical Research, PC.

    Sandy Springs, GA 30328

    Site contact: Jamie Weisman, Site 0072 · 404-939-9220

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, IN 46250

    Site contact: Scott Fretzin, Site 0003 · 317-516-5030

  • Kentucky Advanced Medical Research LLC

    Murray, KY 42071

    Site contact: Hollis Clark, Site 0262

  • Dermatology and Skin Cancer Specialists, LLC

    Rockville, MD 20850

    Site contact: Benjamin Lockshin, Site 0061 · 301-355-3183

  • Kuchnir Dermatology & Dermatologic Surgery

    Milford, MA 01757

    Site contact: Shiu-Chung Au, Site 0220 · 000-000-0000

  • C.S. Mott Clinical Research Center (CRC)

    Detroit, MI 48201

    Site contact: Geoffrey Potts, Site 0095 · 248-581-5243

  • Henry Ford Medical Center

    Detroit, MI 48202-3141

    Site contact: Linda Stein Gold, Site 0065 · 248-884-5356

  • Dermatology and Skin Cancer Center

    Lee's Summit, MO 64064

    Site contact: Mark Fleischman, Site 0266 · 913-451-7546

  • JDR Dermatology Research

    Las Vegas, NV 89148

    Site contact: James Del Rosso, Site 0052 · 702-596-6137

  • Apex Clinical Research Center - Canton

    Canton, OH 44716

    Site contact: Jorge Garcia-Zuazaga, Site 0251 · 14404404430440

  • Apex Clinical Research Center

    Lorain, OH 44053

    Site contact: Garcia-Zuazaga Jorge, Site 0275

  • Apex Clinical Research Center

    Mayfield Heights, OH 44124

    Site contact: Brian Moore, Site 0055 · 440-940-2739

  • Paddington Testing Company

    Philadelphia, PA 19103

    Site contact: Jennifer Parish, Site 0073 · 215-563-7330

  • ObjectiveHealth - Goodlettsville Dermatology Research

    Goodlettsville, TN 37072

    Site contact: Keith Loven, Site 0235 · 615-241-2820

  • Texas Dermatology and Laser Specialists

    San Antonio, TX 78218

    Site contact: John Browning, Site 0033 · 210-704-4037

  • Frontier Derm Partners

    Mill Creek, WA 98012

    Site contact: Eingun Song, Site 0071 · 425-275-4404

Study contacts (from the official record)

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
  • First line of the email MUST contain NCT # and Site #.
All dermatology studies in California →
A Study to Evaluate the Efficacy, Safety, and Drug Levels of… (NCT06979453) | Bored Studies